(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The patient effects of dissection, angina, hematoma, and ischemia are listed in the xience sierra everolimus eluting coronary stent systems instructions for use, as known patient effects of coronary stenting procedures.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the 3.5x38 mm xience sierra stent was implanted in the proximal left anterior descending coronary artery.After the patient left the catheterization (cath) lab, the patient complained of chest pain and had ischemic changes on the electrocardiogram.The patient was immediately brought back to the cath lab for another look.On angiography, the xience sierra stent was widely patent but a new "haziness" was observed at the distal edge of the stent.Optical coherence tomography (oct) demonstrated a significant edge dissection with intramural hematoma.It was subsequently covered with a 3.5x15 mm xience stent.No additional information was provided.
|